We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimens.
- Authors
Burgos, Joaquin; Moreno-Fornés, Sergio; Reyes-Urueña, Juliana; Bruguera, Andreu; Martín-Iguacel, Raquel; Raventos, Berta; Llibre, Josep M; Imaz, Arkaitz; Peraire, Joaquim; Orti, Amat-Joaquim; Dalmau, David; Casabona, Jordi; Miró, Josep M; Falcó, Vicenç; group, the PISCIS study
- Abstract
Objectives To assess the clinical and immunovirological outcomes among naive patients with advanced HIV presentation starting an antiretroviral regimen in real-life settings. Methods This was a multicentre, prospective cohort study. We included all treatment-naive adults with advanced HIV disease (CD4+ T cell count < 200 cells/mm3or presence of an AIDS-defining illness) who started therapy between 2010 and 2020. The main outcomes were mortality, virological effectiveness (percentage of patients with viral load of ≤50 copies/mL) and immune restoration (percentage of patients with CD4+ T cell count above 350 cells/mm3). Competing risk analysis and Cox proportional models were performed. A propensity score-matching procedure was applied to assess the impact of the antiretroviral regimen. Results We included 1594 patients with advanced HIV disease [median CD4+T cell count of 81 cells/mm3and 371 (23.3%) with AIDS-defining illness] and with a median follow-up of 4.44 years. The most common ART used was an integrase strand transfer inhibitor (InSTI) regimen (46.9%), followed by PI (35.7%) and NNRTI (17.4%), with adjusted mortality rates at 3 years of 3.1% (95% CI 1.8%–4.3%), 4.7% (95% CI 2.2%–7.1%) and 7.6% (95% CI 5.4%–9.7%) (P = 0.001), respectively. Factors associated with increased mortality included older age and history of injection drug use, whilst treatment with an InSTI regimen was a protective factor [HR 0.5 (95% CI 0.3–0.9)]. A sensitivity analysis with propensity score procedure confirms these results. Patients who started an InSTI achieved viral suppression and CD4+ T cell count above 350 cells/mm3significantly earlier. Conclusions In this large real-life prospective cohort study, a significant lower mortality, earlier viral suppression and earlier immune reconstitution were observed among patients with advanced HIV disease treated with InSTIs.
- Subjects
HIV infections; ANTIRETROVIRAL agents; DRUG abuse; T cells; TREATMENT effectiveness; IMMUNOSUPPRESSION
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2023, Vol 78, Issue 1, p108
- ISSN
0305-7453
- Publication type
Article
- DOI
10.1093/jac/dkac361